Evaluation of the therapeutic effectiveness of Siddhar Yogam and Seenthil Chooranam (Internal) in the Management of Neerizhivu (Prediabetes) patients reporting at Ayothidoss Pandithar Hospital of National Institute of Siddha, Chennai - A Comparative,Randomized, Double arm Clinical trial
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The outcome of the study will be assessed by reduction in the HbA1c after treatment
研究概览
简要总结
Prediabetes is a serious health condition where blood sugar levels are higher than normal,but not high enough yet to be diagnosed as Type ll Diabetes mellitus .In the Siddha concept,it may be correlated to the Neerizhivu.
Prediabetes mainly due to lifestyle modification, unhealthy eating habits,less physical activity, medical health disorder,under any medication .Hence, considerably more patients of Prediabetes (Neerizhivu) have been recorded in the Ayothidoss Pandithar Hospital.
The Siddha drug Seendhil Chooranam is said to be cost effective and simple medicine and has Antidiabetic,Immunomodulatory, Hepatoprotective, Analgesic , Anti-inflammatory, Antimicrobial and Anti-histamine activities.
Yogasanam plays an important role in the management of blood sugar levels.Yoga can moderate the impact of diabetes is through its effectiveness as a stress -reduction measure.Because high levels of stress hormones like adrenaline and cortisol raise blood sugar levels.
So,I hope Seenthil Chooranam and Yogasanam will be effective in the treatment of Neerizhivu (Prediabetes).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- None
入排标准
- 年龄范围
- 30.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Newly diagnosed Prediabetic subjects with following blood parameters 1) Glucose Tolerance test (
- •200 mg/dl) 2) HbA1c (5.7.
排除标准
- •1.Other Endocrine abnormalities 2.Any other serious Systemic Diseases 3.Myocardial infarction, vascular surgery and stroke in past year 4.Pregnancy, lactation and planning for pregnant.
结局指标
主要结局
The outcome of the study will be assessed by reduction in the HbA1c after treatment
时间窗: Screening-6months | Patient enrollment-6months | Data analysis-1month | Follow up-3months
次要结局
未报告次要终点
研究者
Dr R Sumithra
National Institute of Siddha